Japan’s Biotech Ecosystem: Opportunities, Partnerships and Support Pathways
Date: 29 September 2026
Time: 15:00–16:00 JST / 14:00–15:00 SGT
Venue: Online Webinar
Co-organised by ASEAN-Japan Centre and Enterprise Singapore
About the Webinar
Japan offers one of Asia’s most established healthcare and life sciences markets, supported by advanced clinical infrastructure, a comprehensive regulatory system and public support mechanisms for international companies.
This webinar will provide Singapore biomedical, biotech and healthcare companies exploring entry into Japan with practical guidance from esteemed speakers from Ministry of health, Labour and Welfare, and the National Cancer Centre Japan. It covers Japan’s market-entry pathways, including drug pricing and reimbursement, clinical development and available support mechanisms.
The webinar will also provide relevant Japanese companies, research institutions, investors and ecosystem partners with an opportunity to better understand the needs of Singapore biotech companies and explore potential future business, investment, clinical and research collaboration.
Programme
| Content | Speaker |
|---|---|
| Opening Remarks | Enterprise Singapore |
| Japan’s National Health Insurance Drug Price System Practical overview of Japan’s drug pricing and reimbursement framework, including the pathway from regulatory approval to NHI price listing. | Dr. Yasuhiro Araki Director, Office of Clinical Trial Promotion Research and Development Policy Division, Health Policy Bureau Ministry of Health, Labour and Welfare of Japan |
| ENSEMBLExJ: Supporting Global Biotech Companies Entering Japan Introduction to ENSEMBLExJ, an MHLW-funded public support initiative for global biotech companies exploring entry into Japan, including regulatory, clinical and partner-engagement support. | Dr. Wakao Toga Deputy Director, Strategic Planning Bureau National Cancer Center Japan |
| Q&A | |
| Closing Remarks | ASEAN-Japan Centre |
Who Should Attend
- Singapore biotechnology and drug discovery companies exploring expansion into Japan
- Therapeutics, biologics, cell and gene therapy, and oncology-focused startups
- Clinical development, translational research and business development teams within biotech companies
- Researchers and spin-offs commercialising pharmaceutical innovations
- Japanese pharmaceutical companies, research institutions, investors and ecosystem partners interested in collaborating with Singapore biotechnology companies
Follow-up Opportunities
Participants with concrete business or collaboration interests will have an opportunity to indicate their interest through the post-event questionnaire.
Where relevant and subject to mutual interest, the ASEAN-Japan Centre and Enterprise Singapore may consider facilitating appropriate follow-up connections.
Registration
Participation is free. Prior registration required.
Register here: Webinar Registration – Zoom
Registration deadline: 25 September 2026
